New York State Common Retirement Fund Has $995,000 Holdings in China Biologic Products Holdings, Inc. (CBPO)

New York State Common Retirement Fund decreased its holdings in shares of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) by 13.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,786 shares of the biopharmaceutical company’s stock after selling 1,670 shares during the period. New York State Common Retirement Fund’s holdings in China Biologic Products were worth $995,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. State of New Jersey Common Pension Fund D acquired a new stake in shares of China Biologic Products in the third quarter valued at approximately $439,000. Strs Ohio acquired a new stake in China Biologic Products during the 3rd quarter worth $664,000. AHL Partners LLP acquired a new stake in China Biologic Products during the 2nd quarter worth $842,000. Citigroup Inc. grew its holdings in China Biologic Products by 59.4% during the 2nd quarter. Citigroup Inc. now owns 11,748 shares of the biopharmaceutical company’s stock worth $1,329,000 after acquiring an additional 4,378 shares during the period. Finally, GSA Capital Partners LLP grew its holdings in shares of China Biologic Products by 555.3% in the 2nd quarter. GSA Capital Partners LLP now owns 14,515 shares of the biopharmaceutical company’s stock valued at $1,642,000 after buying an additional 12,300 shares during the period. Institutional investors own 65.13% of the company’s stock.

Shares of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) opened at $78.94 on Friday. The company has a market cap of $2,183.07, a price-to-earnings ratio of 19.88, a P/E/G ratio of 1.00 and a beta of 1.80. China Biologic Products Holdings, Inc. has a 52-week low of $72.21 and a 52-week high of $120.46.

Several brokerages have recently issued reports on CBPO. Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. BidaskClub raised shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. China Biologic Products currently has a consensus rating of “Hold” and a consensus target price of $137.50.

TRADEMARK VIOLATION WARNING: “New York State Common Retirement Fund Has $995,000 Holdings in China Biologic Products Holdings, Inc. (CBPO)” was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://transcriptdaily.com/2018/01/05/new-york-state-common-retirement-fund-has-995000-holdings-in-china-biologic-products-holdings-inc-cbpo.html.

China Biologic Products Profile

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products Holdings, Inc. (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply